The success of copyright’s blockbuster initially fueled a surge for the drug industry, nevertheless recent shifts present a murky outlook for those considering a stake. Lower-cost versions are reducing revenue, and continued legal battles add additional complexity to the equation. While specific companies may still see gains from related services